# US 2025/0154468 A1 · Method for inducing dedifferentiation of adipocytes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0154468 A1
- Document ID: US20250154468A1
- Status: Published application
- Kind: A1
- Application number: 18/619,199
- Filed: 2024-03-28
- Published: 2025-05-15
- Earliest claimed: 2023-11-13
- Assignees: City University of Hong Kong
- Applicants: City University of Hong Kong
- Inventors: Liang ZHANG; Guopan LIU; Yilin PAN; Ying WANG
- Web page: https://patentgrep.com/patent/US20250154468A1

## CPC

- C12N 5/0654: {Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth}
- C12N 5/0653: {Adipocytes; Adipose tissue}
- C12N 5/0655: {Chondrocytes; Cartilage}
- C12N 2501/148: Transforming growth factor alpha [TGF-a]
- C12N 2501/21: Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
- C12N 2501/2306: Interleukin-6 (IL-6)
- C12N 2501/415: Wnt; Frizzeled
- C12N 2501/727: Kinases (EC 2.7.)
- C12N 2506/13: from connective tissue cells, from mesenchymal cells
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention investigates the effects of hypertonicity on adipocytes, revealing its role in inducing the release of mitochondrial extracellular vesicles (MEVs). This release subsequently enhances the secretion of TNF-α, a pro-inflammatory cytokine crucial during stress responses, thereby activating the Wnt/β-catenin signaling pathway responsible for adipocyte dedifferentiation. Through the present method, hypertonicity induces MEVs release and TNF-α secretion, ultimately modulating Wnt/β-catenin signaling and promoting adipocyte dedifferentiation, offering promising therapeutic implications.

## Claims

### Claim 1

A method for inducing dedifferentiation of adipocytes, comprising subjecting one or more adipocytes to a hypertonic solution; and inducing release of mitochondrial extracellular vesicles (MEVs) from the one or more adipocytes to an extracellular environment, wherein released MEVs enhance the secretion of a series of inflammatory genes from the one or more adipocytes, and wherein the series of inflammatory genes activates the Wnt/β-catenin signaling pathway, thereby driving adipocyte dedifferentiation.

### Claim 2 (depends on 1)

The method of claim 1, wherein the series of inflammatory genes comprise TNF-α, IL-6, RIP1, CEBPA, and MCP-1.

### Claim 3 (depends on 1)

The method of claim 1, wherein the one or more adipocytes comprise primarily isolated adipocytes, adipocytes derived from induced pluripotent stem cells (iPSCs) or embryonic stem cells (ESCs), adipocytes from different anatomical locations.

### Claim 4 (depends on 1)

The method of claim 1, wherein the one or more adipocytes comprise 3T3-L1 or stromal vascular fraction (SVF)-derived adipocytes.

### Claim 5 (depends on 1)

The method of claim 1, wherein the adipocyte count of the one or more adipocytes is decreased by at least 3.5 times following hypertonic treatment.

### Claim 6 (depends on 5)

The method of claim 5, wherein the hypertonic treatment results in reductions of 40-60% in the expression of adipogenic markers comprising C/EBPβ, PPAR-γ, and adiponectin.

### Claim 7 (depends on 5)

The method of claim 5, wherein the hypertonic treatment results in increase of 10-20% in the expression of surface markers associated with dedifferentiated adipocytes.

### Claim 8 (depends on 1)

The method of claim 1, wherein the hypertonic solution is formulated to have a hypertonic pressure compared to the surrounding environment, and the hypertonic solution comprises a culture medium and 2% PEG 300.

### Claim 9 (depends on 8)

The method of claim 8, wherein the hypertonic solution further comprises an additive including a preservative, a stabilizer, or a medication.

### Claim 10 (depends on 1)

The method of claim 1, wherein the one or more adipocytes treated with the hypertonic solution exhibit a capability for osteogenic and chondrogenic re-differentiation.

### Claim 11 (depends on 1)

The method of claim 1, further comprising adding a small molecule compound to mitigate apoptosis of the one or more adipocytes induced by hypertonic treatment.

### Claim 12 (depends on 11)

The method of claim 11, wherein the small molecule compound comprises 2-amino-4-(3,4-(methylenedioxy)benzylamino)-6-(3-methoxyphenyl)pyrimidine.

### Claim 13 (depends on 11)

The method of claim 11, wherein the one or more adipocytes exhibit a decrease in the expression of adipogenic genes, coupled with concurrent elevations in the expression of marker genes.

### Claim 14 (depends on 13)

The method of claim 13, wherein the adipogenic genes comprise C/EBPβ, PPAR-γ, and adiponectin.

### Claim 15 (depends on 13)

The method of claim 13, wherein the marker genes comprise Smad 9, Esrrb, and Sox2.

### Claim 16 (depends on 11)

The method of claim 11, wherein the one or more adipocytes exhibit a capability for osteogenic and chondrogenic re-differentiation.
